All In MedTech

FDA Clearance Tracker · P150037-S014

CyPass Micro-Stent

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 9, 2020 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 9, 2020

Approved

Time to decision

111 days

Received Dec 20, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P150037-S014
Device name
CyPass Micro-Stent
Applicant location
Fort Worth, TX
Received
Dec 20, 2019
Decided
Apr 9, 2020
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P150037

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code OGO

FDA's approval statement

As written in FDA's record.

Approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the letter dated October 10, 2019 requesting that you continue the assessment of subjects implanted with the device for a minimum of 10 years to assess the long-term safety profile of the CyPass® System.

Source documents

Other decisions for Alcon Research, Ltd.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.